Clinical Trial

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Study acronym: "NAC-MRI"
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2025 (before its estimated May 20, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn if neoadjuvant chemotherapy (NAC) affects the accuracy of magnetic resonance imaging (MRI) in staging muscle-invasive bladder cancer (MIBC). This study will also assess how tissue changes induced by NAC impact MRI interpretation. The main questions it aims to answer are: Does NAC compromise the accuracy of MRI in staging MIBC? Does NAC-induced tissue change affect the reliability of MRI in tumor assessment? Researchers will compare MRI staging accuracy in MIBC patients who received NAC to those who went directly to surgery, to see if NAC impacts MRI's diagnostic performance. Participants will: Undergo MRI scanning before surgery Receive either NAC or go directly to surgery, depending on their group assignment Have their MRI results compared to histopathological outcomes after surgery
Trial Details
NCT Number NCT07202819
Lead Sponsor Assiut University
Conditions Muscle Invasive Bladder Cancer
Enrollment 76 participants
Start Date 2025-09-01
Primary Completion 2026-05-20 (estimated)
Study Completion 2026-08-20 (estimated)
Updated on ClinicalTrials.gov 2025-10-02